Analyst Rating Update on AbbVie (ABBV)

AbbVie (ABBV) : Zacks Investment Research ranks AbbVie (ABBV) as 3, which is a Hold recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 6 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 13 research analysts is 2.23, which indicates as a Buy.

AbbVie (ABBV) : 13 investment research analysts covering AbbVie (ABBV) have an average price target of $72 for the near short term. The highest target price given by the Brokerage Firm to the stock is $90 and the lowest target is $47 for the short term. Analysts expect the variance to be within $10.71 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity analysts at the Brokerage firm BMO Capital downgrades its rating on AbbVie (NYSE:ABBV). The rating major has initiated the coverage with market perform rating on the shares. Earlier, the shares were rated a Outperform by the brokerage firm. The rating by the firm was issued on June 10, 2016.


AbbVie (NYSE:ABBV): The stock opened at $66.81 on Wednesday but the bulls could not build on the opening and the stock topped out at $67.00 for the day. The stock traded down to $66.23 during the day, due to lack of any buying support eventually closed down at $66.57 with a loss of -0.31% for the day. The stock had closed at $66.78 on the previous day. The total traded volume was 6,355,050 shares.

AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.